Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2alpha activity and methods of treating cancer
OwnerJohn W Reganinventor
Life of this patent
Estimating the term…
Abstract
The present invention provides mehtods for screening for substances which inhibit the interaction between a FP prostanoid receptor and a compoudn having PGF2αalphaactivity, methods for inhibiting the interaction, methods of inhibiting signaling mediated by βbeta-catenin, and methods of treating cancer.
Claims35
A method of screening for substances which inhibit the interaction between a FP prostanoid receptors and a compound having PGF2α activity comprising
- contacting a cell expressing the FP prostanoid receptors with the substance to be screened;
- contacting said cell with said PGF2α compound;
- and
- assaying the presence or absence of interaction between FP prostanoid receptors and PGF2α compound, wherein the absence of an interaction between FP prostanoid receptors and PGF2α compound indicates the substance inhibits the interaction.
A method of screening for substances which inhibit the interaction between a FP prostanoid receptor and a compound having PGF2α activity comprising
- introducing and expressing a polynucleotide which encodes the FP prostanoid receptor;
- contacting said cell expressing the FP prostanoid receptor with the substance to be screened;
- contacting said cell with said PGF2α compound;
- and
- assaying the presence or absence of interaction between FP prostanoid receptor and PGF2α compound, wherein the absence of an interaction between FP prostanoid receptor and PGF2α indicates the substance inhibits the interaction.
A method of inhibiting the interaction between FP prostanoid receptor and a compound having PGF2α activity comprising contacting said FPA with a substance which is capable of inhibiting said interaction.
A method of inhibiting β-catenin signaling comprising contacting a cell expressing FP prostanoid receptor with a substance which is capable of inhibiting the interaction between FP prostanoid receptor and a compound having PGF2α activity.
A method of inhibiting G12 and G13 mediated signaling comprising contacting a cell expressing FP prostanoid receptor with a substance which is capable of inhibiting the interaction between FP prostanoid receptor and a compound having PGF2α activity.
A method of treating cancer comprising administering to a patient in need thereof a substance which inhibits the interaction between FP prostanoid receptor and a compound having PGF2α activity in an amount sufficient to inhibit said interaction.
A method of screening for substances which inhibit β-catenin signaling comprising
- contacting a cell expressing FP prostanoid receptor with the substance to be screened;
- contacting said cell with a compound having PGF2α activity;
- and
- assaying the signaling activity, phosphorylation and/or the subcellular localization of the β-catenin;
- wherein a change in one or more of the signaling activity, phosphorylation and/or the subcellular localization is lower than the signaling activity, phosphorylation and/or the subcellular localization compared to a cell not contacted with the substance indicates the substance inhibits the interaction β-catenin signaling.
A method of screening for a substance for their ability to inhibit cancer cell growth comprising
- contacting a cell expressing FP prostanoid receptor with the substance to be screened;
- contacting said cell with a compound having PGF2α activity;
- and
- assaying the change in cell growth, wherein a decrease in cell growth is indicates an inhibition of cancer cell growth.
Dependencies are inferred from the claim text.